TP53 and neoplasm: The results showed that APG-115 activates p53 in tumor microenvironment (TME) immune cells to promote antitumor immunity, and APG-115 enhances the antitumor effects of anti-PD-1 antibodies in Trp53wt, Trp53mut, and Trp53-deficient (Trp53−/−) syngeneic tumor models.